Children with acute lymphoblastic leukaemia have high plasma levels of total homocysteine at time of diagnosis

References

• Andrew M., David M., Adams M., Ali K., Anderson R., Barnard D., et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251–7
   PubMed Web of Science ®Google Scholar
• van Ommen C. H., Heijboer H., Buller H. R., Hirasing R. A., Heijmans H. S., Peters M. Venous thromboembolism in childhood: a prospective two‐year registry in The Netherlands. J Pediatr 2001; 139: 676–81
   PubMed Web of Science ®Google Scholar
• Andrew M., Monagle P. T., Brooker L. Thromboembolic complications during infancy and childhood. B.C. Decker Inc., Hamilton, London 2000
   Google Scholar
• Ruud E., Holmstrom H., Natvig S., Wesenberg F. Prevalence of thrombophilia and central venous catheter‐associated neck vein thrombosis in 41 children with cancer: a prospective study. Med Pediatr Oncol 2002; 38: 405–10
   PubMedGoogle Scholar
• Chalmers E. Epidemiology of venous thromboembolism in neonates and children. Thromb Res 2005; In press
   Google Scholar
• Thomas R. H. Hypercoagulability syndromes. Arch Intern Med 2001; 161: 2433–9
   PubMedGoogle Scholar
• Mitchell L., Hoogendoorn H., Giles A. R., Vegh P., Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'asparaginase‐induced antithrombin III deficiency. Blood 1994; 83: 386–91
   PubMed Web of Science ®Google Scholar
• Lee A. Y., Levine M. N. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25: 137–45
   PubMed Web of Science ®Google Scholar
• Reller M. D. Congenital heart disease: current indications for antithrombotic therapy in pediatric patients. Curr Cardiol Rep 2001; 3: 90–5
   PubMedGoogle Scholar
• Nowak‐Gottl U., Kosch A., Schlegel N. Thromboembolism in newborns, infants and children. Thromb Haemost 2001; 86: 464–74
   PubMed Web of Science ®Google Scholar
• Nowak‐Gottl U., Heinecke A., von Kries R., Nurnberger W., Munchow N., Junker R. Thrombotic events revisited in children with acute lymphoblastic leukaemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001; 103: 165–72
   PubMed Web of Science ®Google Scholar
• Verso M., Agnelli G. Venous thromboembolism associated with long‐term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665–75
   PubMed Web of Science ®Google Scholar
• Wald D. S., Law M., Morris J. K. Homocysteine and cardiovascular disease: evidence on causality from a meta‐analysis. Br Med J 2002; 325: 1202
   PubMed Web of Science ®Google Scholar
• Stanger O., Weger M., Renner W., Konetschny R. Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease. Clin Chem Lab Med 2001; 39: 725–33
   PubMed Web of Science ®Google Scholar
• Vilaseca M. A., Moyano D., Artuch R., Ferrer I., Pineda M., Cardo E., et al. Selective screening for hyperhomocysteinemia in pediatric patients. Clin Chem 1998; 44: 662–4
   PubMed Web of Science ®Google Scholar
• Coppola A., Davi G., De Stefano. , Mancini F. P., Cerbone A. M., Di Minno G. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000; 26: 243–54
   PubMed Web of Science ®Google Scholar
• Osganian S. K., Stampfer M. J., Spiegelman D., Rimm E., Cutler J. A., Feldman H. A., et al. Distribution of and factors associated with serum homocysteine levels in children: Child and adolescent trial for cardiovascular health. JAMA 1999; 281: 1189–96
   PubMed Web of Science ®Google Scholar
• De Laet C., Wautrecht J. C., Brasseur D., Dramaix M., Boeynaems J. M., Decuyper J., et al. Plasma homocysteine concentration in a Belgian school‐age population. Am J Clin Nutr 1999; 69: 968–72
   PubMed Web of Science ®Google Scholar
• Vilaseca M. A., Moyano D., Ferrer I., Artuch R. Total homocysteine in pediatric patients. Clin Chem 1997; 43: 690–2
   PubMed Web of Science ®Google Scholar
• Refsum H., Wesenberg F., Ueland P. M. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991; 51: 828–35
   PubMed Web of Science ®Google Scholar
• Kishi S., Griener J., Cheng C., Das S., Cook E. H., Pei D., et al. Homocysteine, pharamcogenetics and neurotoxicity in children with leukaemia. J Clin Oncol 2003; 21: 3084–91
   PubMed Web of Science ®Google Scholar
• Cappuccio F. P., Bell R., Perry I. J., Gilg J., Ueland P. M., Refsum H., et al. Homocysteine levels in men and women of different ethnic and cultural background living in England. Atherosclerosis 2002; 164: 95–102
   PubMed Web of Science ®Google Scholar
• Domagala T. B., Adamek L., Nizankowska E., Sanak M., Szczeklik A. Mutations C677T and A1298C of the 5,10‐methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. Blood Coagul Fibrinolysis 2002; 13: 423–31
   PubMed Web of Science ®Google Scholar
• Ueland P. M., Hustad S., Schneede J., Refsum H., Vollset S. E. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22: 195–201
   PubMed Web of Science ®Google Scholar
• Balasa V. V., Gruppo R. A., Glueck C. J., Stroop D., Becker A., Pillow A., et al. The relationship of mutations in the MTHFR, prothrombin, and PAI‐1 genes to plasma levels of homocysteine, prothrombin, and PAI‐1 in children and adults. Thromb Haemost 1999; 81: 739–44
   PubMed Web of Science ®Google Scholar
• Schneede J., Refsum H., Ueland P. M. Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost 2000; 26: 263–79
   PubMed Web of Science ®Google Scholar
• Steinmetz J., Choukalfe A., Visvikis S., Henny J., Slest G. Biological factors affecting concentrations of serum LpAI lipoprotein particles in serum and determination of reference limits. Clin Chem 1990; 36: 806–12
   Google Scholar
• Nowak‐Gottl U., Junker R., Hartmeier M., Koch H. G., Munchow N., Assmann G., et al. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999; 100: 743–8
   PubMed Web of Science ®Google Scholar
• Nowak‐Gottl U., Debus O., Findeisen M., Kassenbohmer R., Koch H. G., Pollmann H., et al. Lipoprotein(a): its role in childhood thromboembolism. Pediatrics 1997; 99: E11
   Google Scholar
• von Depka M., Nowak‐Gottl U., Eisert R., Dieterich C., Barthels M., Scharrer I., et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96: 3364–8
   PubMed Web of Science ®Google Scholar
• Caplice N. M., Panetta C., Peterson T. E., Kleppe L. S., Mueske C. S., Kostner G. M., et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98: 2980–7
   PubMed Web of Science ®Google Scholar
• Constans J., Wendling G., Peuchant E., Camilleri G., Conri C. Lipoprotein(a) in 505 hospitalized patients with various pathological states: correlations with cardiovascular diseases and therapies. Int Angiol 1996; 15: 1–5
   PubMed Web of Science ®Google Scholar
• Nakajima K., Hata Y. Intraindividual variations in lipoprotein (a) levels and factors related to these changes. J Atheroscler Thromb 1996; 2: 96–106
   PubMedGoogle Scholar